Evidence map›Paper›PMID 35566790›Full record

ArticleJournal of clinical medicine2022

Triglyceride-Glucose Index for Early Prediction of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of 121,975 Individuals.

Azizullah Beran, Hazem Ayesh, Mohammed Mhanna, Waseem Wahood, Sami Ghazaleh, Ziad Abuhelwa, Wasef Sayeh, Nameer Aladamat, Rami Musallam, Reem Matar and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Identification of pediatric MASLD using insulin resistance indices.JHEP reports : innovation in hepatology · 2025
    Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Azizullah BeranDepartment of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.ORCID 0000-0002-4161-942X
Hazem AyeshDepartment of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.
Mohammed MhannaDepartment of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.
Waseem WahoodDr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33314, USA.
Sami GhazalehDepartment of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.
Ziad AbuhelwaDepartment of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.
Wasef SayehDepartment of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.
Nameer AladamatDepartment of Neurology, University of Toledo, Toledo, OH 43606, USA.
Rami MusallamDepartment of Internal Medicine, St. Vincent Charity Medical Center, Cleveland, OH 44115, USA.
Reem MatarDepartment of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
Saif-Eddin MalhasDepartment of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.
Ragheb AssalyDepartment of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.
University of Toledo · USMayo Clinic in Arizona · USNova Southeastern University · USSt. Vincent Charity Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin resistance (IR) is a major contributor to the pathogenesis of nonalcoholic fatty liver disease (NAFLD). The triglyceride-glucose (TyG) index has recently gained popularity for the assessment of IR and NAFLD due to its ease of acquisition and calculation. Therefore, we conducted this systematic review and meta-analysis to summarize the existing studies in the literature and provide a quantitative assessment of the significance of the TyG index in predicting the incidence of NAFLD. A comprehensive literature search in PubMed, EMBASE, and Web of Science databases from inception until 25 March 2022 was conducted. Published observational studies that evaluated the association between TyG index and NAFLD among the adult population and reported the hazard ratio (HR) or odds ratio (OR) for this association after multivariate analysis were included. The random-effects model was used as the primary statistical analysis model in the estimation of pooled ORs and HRs with the corresponding confidence intervals (CIs). A total of 17 observational studies, including 121,975 participants, were included. For studies analyzing the TyG index as a categorical variable, both pooled OR (6.00, CI 4.12-8.74) and HR (1.70, CI 1.28-2.27) were significant for the association between TyG index and incident NAFLD. For studies analyzing the TyG index as a continuous variable, pooled OR (2.25, CI 1.66-3.04) showed similar results. Consistent results were obtained in subgroup analyses according to the study design, sample size, ethnicity, and diabetic status. In conclusion, our meta-analysis demonstrates that a higher TyG index is associated with higher odds of NAFLD. TyG index may serve as an independent predictive tool to screen patients at high risk of NAFLD in clinical practice, especially in primary care settings. Patients with a high TyG index should be referred for a liver ultrasound and start intense lifestyle modifications. However, further large-scale prospective cohort studies are necessary to validate our findings.

Indexed as

hepatic steatosisNAFLDNASHnonalcoholic fatty liver diseasetriglyceride-glucose index

Identifiers

PMID35566790
PMCPMC9102411
OpenAlexW4229452732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.